Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Unknown 2Recruiting 2

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Carcinoma, Non-Small-Cell Lung 17Carcinoma, Hepatocellular 8Nasopharyngeal Carcinoma 7Recurrence 6Neoplasms 6Esophageal Neoplasms 6Breast Neoplasms 6Stomach Neoplasms 5Neoplasm Metastasis 5Esophageal Squamous Cell Carcinoma 5Colorectal Neoplasms 5Locally Advanced Rectal Cancer 4Carcinoma, Renal Cell 4Urinary Bladder Neoplasms 3Small Cell Lung Carcinoma 3Sarcoma 3Rectal Neoplasms 3Melanoma 3Head and Neck Neoplasms 3Colonic Neoplasms 3Cholangiocarcinoma 3Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Solid Tumors 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell 2Leukemia, Myeloid, Acute 2Hyperthermia 2Chondrosarcoma 2Carcinoma, Transitional Cell 2

Interventions

Capecitabine 15Oxaliplatin 10spartalizumab 6Irinotecan 6tislelizumab 4Immune Checkpoint Inhibitors 4toripalimab 3Neoadjuvant Therapy 3sintilimab 2camrelizumab 2Radiation 2Fluorouracil 2Celecoxib 2nimotuzumab 1XELOX 1Thymalfasin 1Radiotherapy 1Leucovorin 1Injections 1HMPL-013 1Chemoradiotherapy 1Amifostine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Locally Advanced Rectal Cancer × Immune Checkpoint Inhibitors × Clear all
NCT06281405 2026-04-03

TORCH-iTNT

Fudan University

Phase 2 Recruiting
192 enrolled
Gastrointestinal

Locally Advanced Rectal Cancer

NCT06304987 2024-03-19

Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and PCSK9 Inhibitor for pMMR/MSS Locally Advanced Mid-low Rectal Cancer

Beijing Friendship Hospital

Phase 2 Unknown
50 enrolled
Gastrointestinal

Locally Advanced Rectal Cancer

NCT05245474 2024-01-10

Neoadjuvant Long-course Chemoradiation Plus PD-1 Blockade for Mid-low Locally Advanced Rectal Cancer

Beijing Friendship Hospital

Phase 2 Recruiting
186 enrolled
Gastrointestinal

Locally Advanced Rectal Cancer

NCT05845268 2023-05-06

Total Neoadjuvant Therapy Combined With Tislelizumab for Local Advanced of Middle and Low Rectal Cancer

Beijing Friendship Hospital

Phase 2 Unknown
102 enrolled
Gastrointestinal

Locally Advanced Rectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡